Advance Petroch. (506947)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter sales of ₹13 crore show the company still has an operating revenue base.
• ROCE of 9.56% is positive and higher than its ROE, indicating some pre-financing operating return.
• Book value of ₹37.05 per share provides a tangible asset figure, even though the price is far above it.
• Profit growth of 0.00% means the company is at breakeven, not bleeding losses.
• Small market cap of ₹23 crore leaves scope for a genuine operational recovery if execution improves.

Concerns

• P/E of 254.25 with latest quarter net profit of ₹0 crore means earnings power is almost negligible.
• ROE of 1.33% and 0.00% dividend yield fail to compensate investors for waiting.
• Sales growth of -0.55% and Piotroski F-Score of 3/9 point to weak fundamentals and possible financial stress.
• P/B of 6.33 at ₹234.65 per share versus book value of ₹37.05 leaves no margin of safety.

AI Analysis

Let me apply the same test I would for any chemical company. Advance Petroch operates in commodity chemicals, where customers buy on price and competition never sleeps. Without a cost advantage or a niche, there is no moat. The figures confirm this. The company earns an ROE of only 1.33%, far less than an Indian fixed deposit. ROCE is 9.56%, which is acceptable only if capital is cheap and debt is low, but we have no debt-equity data to verify that. The latest quarter shows sales of ₹13 crore and net profit of ₹0 crore. A P/E of 254.25 is meaningless except to show how thin earnings are. Sales growth is -0.55%, profit growth is 0.00%, and the Piotroski F-score is 3 out of 9. That score is a warning sign. Book value is ₹37.05 per share, yet the market price is ₹234.65, or 6.33 times book. Where is the margin of safety? There is no dividend yield to pay me while I wait. The 52-week range, ₹97.60 to ₹320.75, tells me this stock has been speculative. I am not a trader. I buy businesses, not symbols. At ₹23 crore market cap, this is a tiny enterprise, but small size alone does not make it a good investment. To pay 254 times earnings, I would need years of exceptional growth and expanding returns. I see no evidence of that. The F-score and flat growth point to a company struggling, not compounding. Benjamin Graham said the stock market is a voting machine in the short run and a weighing machine in the long run. Right now, the ballot box has lifted this micro-cap, but the weighing scale shows a business earning almost nothing. I will watch from the sidelines. If price drops closer to book value and operations start generating genuinely higher profits, I will revisit. Until then, this is not an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer